Gene therapy in joint repair

Current Opinion in Orthopaedics

Volumn 9, Issue 6, 1998, Pages 25-30

  Nakamura, Norimasa ^a,b   Frank, Cyril B ^a   Hart, David A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BONE MARROW CELL; GENE THERAPY; GENETIC ENGINEERING; GENETIC MANIPULATION; HUMAN; JOINT INJURY; MOLECULAR BIOLOGY; PRIORITY JOURNAL; STROMA CELL; TISSUE REPAIR; WOUND HEALING;

EID: 0032458318     PISSN: 10419918     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001433-199812000-00005     Document Type: Article

References (44)

1. 1. Frank CB, Bray RC, Hart DA, Shrive NG, Loitz BJ, Matyas JR, Wilson JE: Soft Tissue Healing. In Knee Surgery. Edited by Fu F, Harner CD, Vince KG. Baltimore: Williams & Wilkins; 1994:189-230.
2. 2. Hirshman HP, Daniel DM, Miyasaka K: The fate of unoperated knee ligament injuries. In Knee Ligaments: Structure, Function, Injury, and Repair. Edited by Daniel DM, Akeson WH, O'Connor JJ. New York: Raven Press; 1991:351-364.
3. 3. Lane JM, Gazdag AR: Biologic agents in fracture repair. Curr Opin Orthop 1996, 7:43-49.
4. 4. Evans CH, Robbins PD: Possible orthopaedic application of gene therapy. J Bone Joint Surg Am 1995, 77:1103-1114.
5. 5. Eming SA, Morgan JR, Berger A: Gene therapy for tissue repair: approaches and prospects. Br J Plast Surg 1997, 50:491-500. This paper extensively reviews the concepts of growth factor gene transfer in soft tissue healing and recent experimental trials in several soft tissues.
6. 6. Kaneda Y, Morishita R, Tomita N: Increased expression of DNA cointroduced with nuclear protein in adult rat liver. J Mol Med 1995, 73:289-297.
7. 7. Dzau VJ, Mann MJ, Morishita R, Kaneda Y: Fusigenic viral liposome for gene therapy in cardiovascular disease. Proc Natl Acad Sci U S A 1996, 93:11421-11425.
8. 8. Scherping SC Jr, Schmidt CC, Georgescu HI, Kwoh CK, Evans CH, Woo SL: Effect of growth factors on the proliferation of ligament fibroblasts from skeletally mature rabbits. Connect Tissue Res 1997, 36:1-8.
9. 9. Deie M, Marui T, Allen CR, Hildebrand KA, Georgescu HI, Niyibizi C, Woo SL: The effects of age on rabbit MCL fibroblast matrix synthesis in response to TGF-beta 1 or EGF. Mech Ageing Dev 1997, 97:121-130.
10. 10. Wolfman NM, Hattersley G, Cox K, Celeste AJ, Nelson R, Yamaji N, et al.: Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family. J Clin Invest 1997, 100:321-330. This paper suggests that growth and differentiation factors 5, 6, and 7, members of the TGF-β gene superfamily, could induce differentiation of mesenchymal cells into neotendon and ligament tissues in vivo.
11. 11. Marui T, Niyibizi C, Georgescu HI, Cao M, Kavalkovich KW, Levine RE, Woo SL: Effect of growth factors on matrix synthesis by ligament fibroblasts. J Orthop Res 1997, 15:18-23.
12. 12. Batten ML, Hansen JC, Dahners LE: Influence of dosage and timing of application of platelet-derived growth factor on early healing of the rat medial collateral ligament. J Orthop Res 1996, 14:736-741.
13. 13. Spindler KP, Imro AK, Mayes CE, Davidson JM: Patellar tendon and anterior cruciate ligament have different mitogenic responses to platelet-derived growth factor and transforming growth factor beta. J Orthop Res 1996, 14:542-546.
14. 14. DesRosiers EA, Yahia L, Rivard CH: Proliferative and matrix synthesis response of canine anterior cruciate ligament fibroblasts submitted to combined growth factors. J Orthop Res 1996, 14:200-208.
15. 15. Hildebrand KA, Woo SL, Smith DW, Allen CR, Deie M, Taylor BJ, Schmidt CC: The effects of platelet-derived growth factor-BB on healing of the rabbit medial collateral ligament: an in vivo study. Am J Sports Med 1998, 26:549-554. This study demonstrates that the application of platelet-derived growth factor-BB protein improves the mechanical properties of the healing medial collateral ligament, suggesting the importance of this growth factor in improving healing tissue quality in vivo.
16. 16. Nakamura N, Horibe S, Matsumoto N, Tomita T, Natsuume T, Kaneda Y, et al.: Transient introduction of a foreign gene into healing rat patellar ligament. J Clin Invest 1996, 97:226-231.
17. 17. Nakamura N, Shino K, Natsuume T, Horibe S, Matsumoto N, Kaneda Y, Ochi T: Early biological effect of in vivo gene transfer of platelet-derived growth factor (PDGF)-B into healing patellar ligament. Gene Ther 1998, 5:1165-1170. This paper demonstrates the effect of PDGF gene overexpression on enhanced angiogenesis and collagen synthesis in early ligament healing, using the HVJ liposome method.
18. 18. Ozkan I, Shino K, Nakamura N, Natsu-ume T, Matsumoto N, Horibe S, et al.: Direct in vivo gene transfer to healing rat patellar ligament by intraarterial delivery of HVJ-liposomes. Eur J Clin Invest 1998, 5:1455-1461.
19. 19. Gerich TG, Kang R, Fu FH, Robbins PD, Evans CH: Gene transfer to the rabbit patellar tendon: potential for genetic enhancement of tendon and ligament healing. Gene Ther 1996, 3:1089-1093.
20. 20. Lou J, Manske PR, Aoki M, Joyce ME: Adenovirus-mediated gene transfer into tendon and tendon sheath. J Orthop Res 1996, 14:513-517.
21. 21. Lou J, Kubota H, Hotokezaka S, Ludwig FJ, Manske PR: In vivo gene transfer and overexpression of focal adhesion kinase (pp125 FAK) mediated by recombinant adenovirus-induced tendon adhesion formation and epitenon cell change. J Orthop Res 1997, 15:911-918. This study demonstrates the effect of overexpression of pp125FAK on abnormal tendon adhesion formation. This suggests the relationship between cell-matrix interaction and tissue adhesion.
22. 22. Crooke ST, Bennett CF: Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 1996, 36:107-129.
23. 23. Nakamura N, Timmermann SA, Hart DA, Kaneda Y, Shrive NG, Shino K, Ochi T, Frank CB: A comparison of in vivo gene delivery methods for antisense therapy in ligament healing. Gene Ther 1998, in press. This study is the first demonstration of an efficient in vivo antisense gene therapy model in soft tissue repair. This study also shows the importance of the selection of surgical gene delivery method for optimizing gene transfer efficiency, in addition to the selection of vectors.
24. 24. Newman AP: Articular cartilage repair. Am J Sports Med 1998, 26:309-324. This paper comprehensively reviews the basic science background of cartilage repair and experimental and clinical therapeutic trials for improving repair.
25. 25. Hering TM: Molecular biology of cartilage repair. In Osteoarthritic Disorders. Edited by Kuettner KE, Goldberg VM. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1995:329-340.
26. 26. Wozney JM, Rosen V: Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair. Clin Orthop 1998, 346:26-37.
27. 27. Wakitani S, Imoto K, Kimura T, Ochi T, Matsumoto K, Nakamura T: Hepatocyte growth factor facilitates cartilage repair. Full thickness articular cartilage defect studied in rabbit knees. Acta Orthop Scand 1997, 68:474-480. This paper suggests the possible application of a novel chondrogenic growth factor, hepatocyte growth factor, for cartilage repair in vivo .
28. 28. Poole AR: Imbalance of anabolism and catabolism of cartilage matrix components in osteoarthritis. In Osteoarthritic Disorders. Edited by Kuettner KE, Goldberg VM. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1995:247-260.
29. 29. Bandara G, Mueller GM, Galea-Lauri J, Tindal MH, Georgescu HI, Suchanek MK, et al.: Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A 1993, 90:10764-10768.
30. 30. Nita I, Ghivizzani SC, Galea-Lauri J, Bandara G, Georgescu HI, Robbins PD, Evans CH: Direct gene delivery to synovium: an evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996, 39:820-828.
31. 31. Ghivizzani SC, Lechman ER, Tio C, Mule KM, Chada S, McCormack JE, et al.: Direct retrovirus-mediated gene transfer to the synovium of the rabbit knee: implications for arthritis gene therapy. Gene Ther 1997, 4:977-982.
32. 32. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, et al.: In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum 1997, 40:1012-1019. This study is the first experimental study showing potential feasibility of gene therapy to prevent osteoarthritis.
33. 33. Bakker AC, Joosten LA, Arntz OJ, Helsen MM, Bendele AM, van de Loo FA, van den Berg WB: Prevention of murine collagen-induced arthritis in the knee and ipsilateral paw by local expression of human interleukin-1 receptor antagonist protein in the knee. Arthritis Rheum 1997, 40:893-900.
34. 34. Ghivizzani SC, Lechman ER, Kang R, Tio C, Kolls J, Evans CH, Robbins PD: Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci U S A 1998, 95:4613-4618. This study demonstrates the effectiveness of direct in vivo gene transfer of soluble receptors of interleukin-1 and tumor necrosis factor-α to the knees of rabbits with antigen-induced arthritis. Moreover this study shows that anti-arthritic effects were also seen in contralateral control knees, suggesting that sustained local inhibition of disease activity in one joint might confer an anti-arthritic effect on other joints.
35. 35. Day CS, Kasemkijwattana C, Menetrey J, Floyd SS Jr, Booth D, Moreland MS, Fu FH, Huard J: Myoblast-mediated gene transfer to the joint. J Orthop Res 1997, 15:894-903.
36. 36. Baragi VM, Renkiewicz RR, Jordan H, Bonadio J, Hartman JW, Roessler BJ: Transplantation of transduced chondrocytes protects articular cartilage from interleukin 1-induced extracellular matrix degradation. J Clin Invest 1995, 96:2454-2460.
37. 37. Kang R, Marui T, Ghivizzani SC, Nita IM, Georgescu HI, Suh JK, et al.: Ex vivo gene transfer to chondrocytes in full-thickness articular cartilage defects: a feasibility study. Osteoarthritis Cartilage 1997, 5:139-143.
38. 38. Tomita T, Hashimoto H, Tomita N, Morishita R, Lee SB, Hayashida K, et al.: In vivo direct gene transfer into articular cartilage by intraarticular injection mediated by HVJ (Sendai virus) and liposomes. Arthritis Rheum 1997, 40:901-906. This study is the first successful demonstration of in vivo gene transfer to articular cartilage.
39. 39. Fang J, Zhu YY, Smiley E, Bonadio J, Rouleau JP, Goldstein SA, et al.: Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci U S A 1996, 93:5753-5758.
40. 40. Lieberman JR, Le LQ, Wu L, Finerman GA, Berk A, Witte ON, Stevenson S: Regional gene therapy with a BMP-2-producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 1998, 16:330-339. This study is a successful BMP-2 gene therapy in large segmental bone defects in the rats using the ex vivo strategy. This paper further demonstrates the morphological difference in the pattern of bone formation between the gene transferred defects and those treated with recombinant human BMP-2, suggesting the importance of continuous expression of BMP-2 at the site of repair for the proper formation of bony trabecular architecture.
41. 41. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
42. 42. Prockop DJ: What holds us together? Why do some of us fall apart? What can we do about it? Matrix Biol 1998, 16:519-528.
43. 43. Allay JA, Dennis JE, Haynesworth SE, Majumdar MK, Clapp DW, Shultz LD, et al.: LacZ and interleukin-3 expression in vivo after retroviral transduction of marrow-derived human osteogenic mesenchymal progenitors. Hum Gene Ther 1997, 8:1417-1427. This paper demonstrates that genetically modified bone marrow stromal cells can be expanded without losing their multidifferentiation potential. These results encourage the future cell-based therapy for improving various tissue repairs.
44. 44. Onyia JE, Clapp DW, Long H, Hock JM: Osteoprogenitor cells as targets for ex vivo gene transfer. J Bone Miner Res 1998, 13:20-30. This paper also demonstrates that genetically modified bone marrow osteoprogenitor cells can be expanded without losing their osteogenic potential.